A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This study is a phase II clinical trial of SSGJ-612 combined with a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC) in patients with hormone receptor (HR)-positive, HER2-low or HER2-ultralow metastatic breast cancer.
Epistemonikos ID: 5a8cb4cad26d657ebca6746384b2f6ec0364f7e2
First added on: Aug 12, 2026